BACKGROUND: Schizophrenia is a complex, multifactorial psychiatric disorder. Our previous findings indicated that altered functional activity of the complement system, a major mediator of the immune response, is implicated in the pathogenesis of schizophrenia. In order to explore whether these alterations are genetically determined or not, in the present study we evaluated the possible association of complement C1Q component gene variants with susceptibility to schizophrenia in Armenian population, focusing on four frequent single nucleotide polymorphisms (SNPs) of C1QA and C1QB genes. METHODS: In the present study four SNPs of the complement C1Q component genes (C1QA: rs292001, C1QB rs291982, rs631090, rs913243) were investigated in schizophrenia-affected and healthy subjects. Unrelated Caucasian individuals of Armenian nationality, 225 schizophrenic patients and the same number of age- and sex-matched healthy subjects, were genotyped. Genotyping was performed using polymerase chain reaction with sequence-specific primers (PCR-SSP) and quantitative real-time (qRT) PCR methods. RESULTS: While there was no association between C1QA rs292001, C1QB rs913243 and rs631090 genetic variants and schizophrenia, the C1QB rs291982*G minor allele was significantly overrepresented in schizophrenic patients (G allele frequency 58%) when compared to healthy subjects (46%, OR = 1.64, p(corr) = 0.0008). Importantly, the susceptibility for schizophrenia was particularly associated with C1QB rs291982 GG genotype (OR = 2.5, p(corrected) = 9.6E-5). CONCLUSIONS: The results obtained suggest that C1QB gene may be considered as a relevant candidate gene for susceptibility to schizophrenia, and its rs291982*G minor allele might represent a risk factor for schizophrenia at least in Armenian population. Replication in other centers/populations is necessary to verify this conclusion.
BACKGROUND:Schizophrenia is a complex, multifactorial psychiatric disorder. Our previous findings indicated that altered functional activity of the complement system, a major mediator of the immune response, is implicated in the pathogenesis of schizophrenia. In order to explore whether these alterations are genetically determined or not, in the present study we evaluated the possible association of complement C1Q component gene variants with susceptibility to schizophrenia in Armenian population, focusing on four frequent single nucleotide polymorphisms (SNPs) of C1QA and C1QB genes. METHODS: In the present study four SNPs of the complement C1Q component genes (C1QA: rs292001, C1QBrs291982, rs631090, rs913243) were investigated in schizophrenia-affected and healthy subjects. Unrelated Caucasian individuals of Armenian nationality, 225 schizophrenicpatients and the same number of age- and sex-matched healthy subjects, were genotyped. Genotyping was performed using polymerase chain reaction with sequence-specific primers (PCR-SSP) and quantitative real-time (qRT) PCR methods. RESULTS: While there was no association between C1QArs292001, C1QBrs913243 and rs631090 genetic variants and schizophrenia, the C1QBrs291982*G minor allele was significantly overrepresented in schizophrenicpatients (G allele frequency 58%) when compared to healthy subjects (46%, OR = 1.64, p(corr) = 0.0008). Importantly, the susceptibility for schizophrenia was particularly associated with C1QBrs291982 GG genotype (OR = 2.5, p(corrected) = 9.6E-5). CONCLUSIONS: The results obtained suggest that C1QB gene may be considered as a relevant candidate gene for susceptibility to schizophrenia, and its rs291982*G minor allele might represent a risk factor for schizophrenia at least in Armenian population. Replication in other centers/populations is necessary to verify this conclusion.
Authors: Karine R Mayilyan; James N Arnold; Julia S Presanis; Armen F Soghoyan; Robert B Sim Journal: Neurosci Lett Date: 2006-07-24 Impact factor: 3.046
Authors: Emily G Severance; Kristin L Gressitt; Meredith Halling; Cassie R Stallings; Andrea E Origoni; Crystal Vaughan; Sunil Khushalani; Armin Alaedini; Didier Dupont; Faith B Dickerson; Robert H Yolken Journal: Neurobiol Dis Date: 2012-07-16 Impact factor: 5.996
Authors: Y M Mosaad; A Hammad; Z Fawzy; A El-Refaaey; Z Tawhid; E M Hammad; L F Youssef; E A A ElAttar; D F Radwan; I M Fawzy Journal: Clin Exp Immunol Date: 2015-07-28 Impact factor: 4.330
Authors: Emily G Severance; Kristin L Gressitt; Stephen L Buka; Tyrone D Cannon; Robert H Yolken Journal: Schizophr Res Date: 2014-09-04 Impact factor: 4.939